Uso de plantas medicinais e medicamentos fitoterápicos por pacientes em tratamento antineoplásico : possíveis interações

• Autor(a) principal: Caetano, Natália Lima de Barros
• Data de Publicação: 2016
• Tipo de documento: Dissertação
• Idioma: por
• Título da fonte: Repositório Institucional da UFS
• Texto Completo: https://ri.ufs.br/handle/riufs/3789
• topic: Ciências da saúde; Plantas medicinais; Oncologia; Fitoterapia; Medicina tradicional; Medical oncology; Phytotherapy; Medicine traditional; CIENCIAS DA SAUDE

The medicinal plants (MP) and herbal medicines (HM) are used for treatment, cure and prevention of diseases. This millenar practice has gained spotlight due to it is hight use by cancer patients, which see these strategies, a way to have control over disease. However, usually, both patients and healthcare professionals are unaware of the possible interactions that may exist between MPs and the conventional treatment that can cause harm to the increase toxicity of antineoplastic compromising the therapeutic efficacy. Therefore, this study aimed to use of MP and/or HM by oncological patients served in the private health system of the state of Sergipe. Were interviewed patients older than 18 years in anticancer treatment and used a questionnaire validated by Vieira (2008). Statistical analyzes were performed using Microsoft Excel version 2010. The project was approved by the Ethics Committee on Research Involving Human Subjects of the opinion whose number is 496.966. Among 331 individuals interviewed, 64.65% they came from the state capital, Aracaju. The average age corresponds to 59.3 years with female predominance 66.77%. Among the administered antineoplastic more often stands out paclitaxel (8.76%). As to use of MP and/or HM, 49.55% affirmed make use of this millenary practice. Regarding more MP is used to lemongrass (43.29%), chamomile (39.02%) and boldo (29.89%) in turn the most frequent HM were propolis (3.05%) and avelos (1.83%). The most common use of reason was "to improve the quality of life", and most individuals (53.66%) reported the oncologist who used MP and/or HM. Detected a potential plant-drug interaction between MP holy grass Cymbopogon citratus (DC.) Stapf and antineoplastic cyclophosphamide. Thirty (30) days after the interview subjects were reassessed on the continued use of MP and/or HM, obtained a result in which 17 (10.36%) discontinued the use of this alternative practice and 10 individuals (6.09%) were excluded due to death. Given these results, it is urgent to implement a rational treatment plan the use of MP/HM in oncology in order to ensure safe pharmacotherapy to the patient minimizing the risk of potential interactions.